Augbio
1 known investors
Find your way into Augbio
Sign up to see every warm intro you have to Augbio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Augbio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Augbio (trading as Vaxanix) develops immuno-oncology therapeutics including multi-neoantigen cancer vaccines and CAR-T cell therapies designed to address antigen escape in solid and hematological tumors. The company also offers platform technologies for immune modulation and cellular therapeutics targeting unmet needs in cancer treatment.
Investors · 1
OS Fundlisted by OS FundPark Ridge · $1M – $2M
How we know: the VCSheet dataset · Not right? Tell us
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $221.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Augbio do?
- Augbio (trading as Vaxanix) develops immuno-oncology therapeutics including multi-neoantigen cancer vaccines and CAR-T cell therapies designed to address antigen escape in solid and hematological tumors. The company also offers platform technologies for immune modulation and cellular therapeutics targeting unmet needs in cancer treatment.
- Who are Augbio's investors?
- Augbio's investors include OS Fund.
